Generation and Characterization of Specific Antibodies to the Murine and Human Ectonucleotidase NTPDase8 by Julie Pelletier et al.
fphar-08-00115 March 8, 2017 Time: 12:17 # 1
ORIGINAL RESEARCH
published: 08 March 2017
doi: 10.3389/fphar.2017.00115
Edited by:
Kenneth A. Jacobson,
National Institutes of Health, USA
Reviewed by:
Gennady G. Yegutkin,
University of Turku, Finland
Terence L. Kirley,
University of Cincinnati, USA
*Correspondence:
Jean Sévigny
jean.sevigny@crchul.ulaval.ca
Specialty section:
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 17 January 2017
Accepted: 24 February 2017
Published: 08 March 2017
Citation:
Pelletier J, Salem M, Lecka J,
Fausther M, Bigonnesse F and
Sévigny J (2017) Generation
and Characterization of Specific
Antibodies to the Murine and Human
Ectonucleotidase NTPDase8.
Front. Pharmacol. 8:115.
doi: 10.3389/fphar.2017.00115
Generation and Characterization of
Specific Antibodies to the Murine
and Human Ectonucleotidase
NTPDase8
Julie Pelletier1, Mabrouka Salem1,2, Joanna Lecka1,2, Michel Fausther1,2,3,
François Bigonnesse1 and Jean Sévigny1,2*
1 Centre de recherche du CHU de Québec – Université Laval, Québec City, QC, Canada, 2 Département de
Microbiologie-Infectiologie et d’Immunologie, Faculté de Médecine, Université Laval, Québec City, QC, Canada,
3 Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arkansas for Medical
Sciences, Little Rock, AR, USA
The ectonucleotidase nucleoside triphosphate diphosphohydrolase-8 (NTPDase8) is the
last member of the Ecto-NTPDase family to be discovered and characterized. It is a
transmembrane protein which regulates the concentration of the agonists of P1 and
P2 receptors at the cell surface. The functions of the enzyme are still not known partly
due to the lack of specific tools such as antibodies. In this work, guinea pig polyclonal
antibodies against mouse NTPDase8 and mouse monoclonal antibodies against human
NTPDase8 have been generated and characterized. For the production of antibodies
against mouse NTPDase8 several techniques have been tried. Several peptide antigens
in several hosts (rabbit, rat, hamster, and guinea pig) failed to give a positive reaction
suggesting that NTPDase8 is poorly immunogenic. In this study, we describe the
successful process that led to anti-mouse NTPDase8, namely the cDNA immunization
technique. Monoclonal antibodies to human NTPDase8 were also obtained by cDNA
immunization followed by a final injection with transfected human embryonic kidney
(HEK 293T) cells expressing human NTPDase8. The specificity of these antibodies
was evaluated by Western blot, immunocytochemistry, immunohistochemistry and flow
cytometry. In contrast, all commercial antibodies to NTPDase8 peptides that we have
tested failed to give a specific positive signal against the expressed NTPDase8 protein
when used to probe Western blots. In addition, immunohistochemistry experiments
confirmed the presence of NTPDase8 in mouse liver canaliculi. The tools generated
in this work will help characterize NTPDase8 localization and function in future studies
and its contribution to the modulation of P1 and P2 receptor activation.
Keywords: monoclonal antibodies, polyclonal antibodies, mouse NTPDase8, human NTPDase8, cDNA
immunization
INTRODUCTION
The activation of nucleotide (P2) and adenosine (P1) receptors is regulated in part by enzymes
that regulate the concentration of their agonists at the cell surface. The most important
enzymes that dephosphorylate nucleotides in the extracellular environment in physiological
conditions are members of the Ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase)
family (Beaudoin et al., 1996; Robson et al., 2006; Zimmermann et al., 2012). This family
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of ectonucleotidases is composed of 8 members (NTPDase1 to -8;
Robson et al., 2006; Zimmermann et al., 2012). NTPDase1, -2, -3,
and -8 are expressed at the plasma membrane and they hydrolyse
nucleotides at the cell surface with different abilities (Kukulski
et al., 2005). These enzymes have been located in different systems
and they have been reported to play distinct roles. To give a few
examples, NTPDase1, which is expressed by several cell types
which includes vascular endothelial cells and Tregs, has been
shown to regulate vascular hemostasis and immune functions
(Kukulski et al., 2011; Zimmermann et al., 2012; Yegutkin, 2014).
NTPDase2, which is also expressed by several cell types, is found
in type I cells of taste buds where it has been associated to
taste functions (Bartel et al., 2006; Vandenbeuch et al., 2013).
NTPDase3 has been detected in neurons in different organs. It
was proposed that in the rat brain, NTPDase3 may modulate
feeding and sleep–wake behavior (Belcher et al., 2005). In contrast
to NTPDase1, -2, and -3, no function has yet been associated
to NTPDase8. Finally, as NTPDase4, -5, -6, and -7 are mainly
anchored to the membranes of intracellular organelles and as they
hydrolyse nucleotides with lower affinities their functions are
expected to differ from the one of the above plasma membrane
bound NTPDases.
So far NTPDase8 was reported to be expressed only in a few
tissues which includes rat (Fausther et al., 2007) and porcine
(Sévigny et al., 2000) liver, and pig kidneys (Sévigny et al.,
2000). The lack of tools such as antibodies limits the study of
NTPDase8 structure and function. To date, some commercial
antibodies against NTPDase8 are available, but their specificity
has not been demonstrated. The goal of this work was to
obtain specific antibodies against NTPDase8 and to demonstrate
their specificity. As the commercial antibodies revealed to be
unspecific, to achieve this goal we used several techniques of
immunization. Following several unsuccessful attempts we finally
ended with a convenient technique that we also describe here.
MATERIALS AND METHODS
Materials
Aprotinin, phenylmethanesulfonyl fluoride, ethylenediamine-
tetraacetic acid, sodium citrate, paraformaldehyde (PFA),
3,3′-diaminobenzidine (DAB), and hydrogen peroxide (H2O2)
were purchased from Sigma-Aldrich (Oakville, ON, Canada).
Tris(hydroxymethyl)aminomethane (Tris) was from VWR
International (Montreal, QC, Canada). Dulbecco’s modified
Eagle’s medium and antibiotic–antimycotic solution, NuPAGE
lithium dodecyl sulfate sample, NuPAGE 4–12% Bis-Tris
gels were obtained from Life Technologies (Burlington, ON,
Canada). Fetal bovine serum (FBS) and goat serum were from
Wisent (St-Bruno, QC, Canada). For Western blot and/or
immunohistochemistry experiments the secondary antibodies
used were either conjugated to horseradish peroxidase (HRP),
namely goat anti-guinea pig, donkey anti-goat (Santa Cruz
Biotechnology, Dallas, TX, USA), goat anti-mouse (Jackson
ImmunoResearch Laboratories Inc. West Grove, PA, USA),
donkey anti-rabbit (GE Healthcare Life Sciences, Baie d’Urfe,
QC, Canada), rabbit anti-rat (Thermo Fisher Scientific, Rockford,
IL, USA), or to biotin, namely goat anti-guinea pig, goat anti-
rabbit (Jackson ImmunoResearch Laboratories Inc. West
Grove, PA, USA), goat anti-mouse and goat anti-rat (Vector
Laboratories, Burlington, ON, Canada). For flow cytometry
experiments Alexa Fluor 594-goat anti-guinea pig and Alexa
Fluor 633-goat anti-mouse were obtained from Life Technologies
(Burlington, ON, Canada).
Animals and Plasmids
Female Sprague-Dawley rats, Hartley guinea pigs, LVG Golden
Syrian hamsters, BALB/c mice, and New Zealand rabbits were
obtained from Charles River Laboratories (Saint-Constant, QC,
Canada). All procedures were approved by the Canadian Council
on Animal Care and the Université Laval Animal Welfare
Committee. The plasmids encoding mouse NTPDase1 (GenBank
accession no. NM_009848; Enjyoji et al., 1999), mouse NTPDase2
(AY376711; Kukulski et al., 2005), mouse NTPDase3 (AY376710;
Lavoie et al., 2004), mouse NTPDase8 (AY364442; Bigonnesse
et al., 2004), human NTPDase1 (U87967; Kaczmarek et al., 1996),
human NTPDase2 (NM_001246; Knowles and Chiang, 2003), a
kind gift of Dr. A. F. Knowles (San Diego, CA, USA), human
NTPDase3 (AF034840; Smith and Kirley, 1998), a kind gift
of Dr. T. L. Kirley (Cincinnati, OH, USA), human NTPDase8
(AY430414; Fausther et al., 2007), or rat NTPDase8 (AY536920;
Fausther et al., 2007) all in pcDNA 3.1 vector were used for
antiserum generation and for/or cell transfection, as described
below.
Polyclonal Antibody Production to
Mouse NTPDase8 with Peptides and
Recombinant Proteins Produced in
Bacteria
High density multiple antigen peptides (MAPs) system
generated using four lysine residues bearing four branching
peptides were synthesized separately with two polypeptides:
peptide 829 (MGLSWKERVFMALL) and peptide 830
(QWPANKEKDTGVVSQ) that correspond to amino acid
1–14 and 60–74, respectively. These two antigens were generated
by the Proteomics Platform of the Centre de Recherche of the
CHU de Québec. These peptides were injected at day 1, 43,
85, 127, 169, 211 in rabbits, at day 1, 29, 57, 92 in hamsters,
and at day 1, 29, 57, 92, 146 in guinea pigs and rats. The
amount of peptides injected was as follows: 400–650 µg for
rabbits, 100–200 µg for rats and guinea pigs, and 100 µg for
hamsters. The blood was collected prior to the first injection and
7 days post-injection. The peptides were diluted in phosphate-
buffered solution (PBS) (in mM: 10.1 Na2HPO4, 1.8 KH2PO4,
136.9 NaCl, and 2.7 KCl, pH 7.4) and complete Freund’s
adjuvant was mixed at a ratio 1:1 with peptides for the first
injection. Two other peptides conjugated to keyhole limpet
hemocyanin (KLH) that correspond to amino acid 87-101
(SYTSDPTQAGESLKS) and 390-404 (VEVSYPGQERWLRDY)
were also injected six times (125–250 µg) in rabbit. The blood
was collected 7 days post-injection. Recombinant purified
protein produced in bacteria corresponding to amino acid
361–441 of mouse NTPDase8, named as peptide 76, was
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synthetized by the Molecular Biology and Production of
Antibody Service of the Centre de Recherche du CHU de
Québec. Rabbits were injected three times at day 1, 28, 56 and
blood was collected 14 days after the second and the third
injection.
Polyclonal Antibodies by cDNA
Immunization
Genetic immunization was carried out with plasmids encoding
mouse NTPDase8 diluted in PBS 0.8×. Rabbits were injected with
1 mL of mouse NTPDase8 cDNA (0.65–0.8 mg/mL) consisting of
10 intradermic (ID) sites of 50 µL each and two intramuscular
(IM) sites of 250 µL each. Hamsters were injected with 0.1 mL
of mouse NTPDase8 cDNA (1 mg/mL) consisting of two ID sites
of 25 µL each and one IM site of 50 µL. Guinea pigs and rats
were injected with 0.2 mL of mouse NTPDase8 cDNA (1 mg/mL)
consisting of two ID sites of 50µL each and one IM site of 100µL.
Rabbits and hamsters were injected at day 1, 15, 29, 99, 183, 253,
286, 316, 384, and at day 1, 15, 29, 99, 170, respectively, rats
and guinea pigs were injected at day 1, 15, 29, 99, 170, 283. The
intradermal injections were done in the dorsal skin and the IM
injections were done in the hind leg. The blood was collected
prior to the first injection and between 12 and 14 days after the
third and the subsequent injection.
Monoclonal Antibody Production by
cDNA Immunization
Hybridomas were generated in BALB/c mice by ID and IM
injection with 100 µg of human NTPDase8 cDNA diluted in PBS
0.8× at day 1, 15, 29, 99, and 184. A final injection was made
at day 297 using intact human embryonic kidney (HEK 293T)
cells transfected with human NTPDase8 expression vector (see
Cell Transfection and Western Blot). Spleen cells were collected
3 days after the prime boost cells injection and fusion with
SP2/0 cells were done as previously described (Munkonda et al.,
2009) with minor modifications. For this assay, the SP2/0 cells
were combined with splenocytes at a ratio 1:5. The positive
hybridomas were screened by enzyme-linked immunosorbent
assay (ELISA). The hybridomas were cloned by limiting dilution
and the produced immunoglobulins were purified on Protein A
Sepharose CL-4B column as described (Munkonda et al., 2009).
ELISA and Isotyping for Monoclonal
Antibodies
ELISA plates (96 wells) were coated overnight (O/N) with
500 ng per well of lysates from African green monkey kidney
(COS-7) cells transiently transfected with human NTPDase8
or untransfected diluted in PBS. After washing with PBS-
Tween 0.05% (PBS-T), the wells were incubated for 1 h at
37◦C in a blocking solution (0.5% bovine serum albumin
diluted in PBS-T). After washing, the supernatant from each
hybridoma was added to the well and incubated for 2 h at
room temperature (RT), followed by four washing steps. Then
a goat anti-mouse IgG (H + L)-HRP (1:2500) diluted in the
blocking solution was incubated for 2 h at RT followed by
four washing steps. The Enhanced K-Blue R© Substrate (Neogen
Corporation, Lansing, MI, USA) was then added for 15 min and
the reaction was stopped by the addition of an equal volume
of 2 N sulphuric acid and absorbance at 450 nm was recorded.
The isotype of the antibodies produced by each hybridoma
was determined by a Mouse Immunoglobulin Isotyping ELISA
Kit (BD Bioscience, Mississauga, ON, Canada) according to
the manufacturer’s instruction. In brief, monoclonal rat anti-
mouse IgG1, IgG2a, IgG2b, IgG3, IgA, and IgM were coated
O/N in 96-well plates. After a washing step and a blocking
treatment, each monoclonal anti-human NTPDase8 antibody
was transferred to the wells. After washing steps, a rat anti-
mouse Ig conjugated to HRP was added to each well, and revealed
with a substrate provided in the kit. The plate was then read at
450 nm.
Cell Transfection and Western Blot
COS-7 cells and HEK 293T cells were cultured and transiently
transfected as indicated with mouse NTPDase8 or human
NTPDase8 cDNA constructs as described previously (Kukulski
et al., 2005). For Western blot assays, lysates from transfected or
non-transfected COS-7 cells (6 µg, unless otherwise indicated)
were resuspended in NuPAGE sample buffer, separated on
NuPAGE 4–12% Bis-Tris gels under reduced or non-reduced
conditions, as indicated, and transferred to an Immobilon-P
membrane (Millipore, Bedford, MA, USA) by electroblotting
according to the manufacturer’s recommendation. Membranes
were then blocked with 2.5% non-fat milk in PBS containing
0.15% Tween20 R©(pH 7.4) O/N at 4◦C and subsequently probed
with the primary antibodies. Appropriate secondary HRP-
conjugated antibodies were used, and the membranes developed
with the Western LightningTM Plus-ECL system (PerkinElmer
Life and Analytical Sciences, Waltham, MA, USA). In some
experiments, a gel with a large sample well 6 cm long containing
120 µg of lysates, transferred and blocked as described above
and then probed with antibodies using the Mini-Protean II
multiscreen apparatus (Bio-Rad Laboratories Ltd., Mississauga,
ON, Canada) in which 20 antibodies can be tested on
one gel.
Immunocytochemistry and
Immunohistochemistry
Mouse liver was collected after animal perfusion with 4% PFA,
tissues were then fixed in 4% PFA for 2 h and incubated O/N
in 4% sucrose at 4◦C and frozen in Tissue-Tek R© O.C.T.TM
Compound (Sakura Finetek, Torrance, CA, USA). COS-7 cells
or tissues sections (6 µm thick) of mouse liver were fixed in
10% phosphate-buffered formalin (Fisher Scientific, Ottawa, ON,
Canada) mixed with cold acetone (Fisher Scientific, Ottawa,
ON, Canada) and blocked in a PBS solution containing
7% normal goat serum for 30 min. COS-7 cells and tissue
sections were incubated with the indicated primary antibody
at 4◦C. COS-7 cells and tissue sections were then treated with
0.15% H2O2 in PBS for 10 min to inactivate endogenous
peroxidase, and with an avidin/biotin solution (Avidin/Biotin
Blocking kit; Vector Laboratories, Burlington, ON, Canada)
to prevent non-specific staining due to endogenous biotin.
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This step was followed by incubation with an appropriate
biotin-conjugated secondary antibody at a dilution of 1:1000.
The avidin–biotinylated HRP complex (VectaStain Elite ABC
kit; Vector Laboratories) was added to optimize the reaction.
Peroxidase activity was revealed with DAB as the substrate.
Nuclei were counterstained with aqueous hematoxylin (Biomeda,
Foster City, CA, USA) in accordance with the manufacturer’s
instructions.
Flow Cytometry (FACS)
HEK 293T cells transfected with mouse or human NTPDase8,
were detached from the plates with a citric saline solution
(135 mM potassium chloride, 15 mM sodium citrate). Samples
of 2.5 × 105 cells per tube were washed with an ice-cold
PBS solution containing 1% FBS and 0.1% NaN3 [fluorescence-
activated cell sorting (FACS) buffer] followed by incubation
with the primary antibodies (serum from polyclonal anti-
mouse NTPDase8 or purified monoclonal antibodies to human
NTPDase8) or negative control (guinea pig preimmune sera or
control mouse IgG2a (Sigma-Aldrich, Oakville, ON, Canada)) in
FACS buffer for 1 h. After washes with FACS buffer solution,
the cells were incubated with an appropriate Alexa-conjugated
secondary antibody for 30 min on ice, washed with FACS buffer,
and analyzed by flow cytometry (BD LSR II, BD Biosciences, San
Jose, CA USA).
Inhibition Assays
Inhibition assay were done as previously described (Munkonda
et al., 2009) on cell lysates from human NTPDase8 transfected
COS-7 cells at 37◦C in two different buffers: modified Ringer
buffer (120 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.2 mM
MgSO4, 25 mM NaHCO3, 5 mM dextrose, 80 mM Tris–HCl,
pH 7.4) and Tris/calcium buffer (5 mM CaCl2, 80 mM Tris–
HCl, pH 7.4). After pre-incubation of the enzyme with the
purified monoclonal antibodies to human NTPDase8 (5 µg/mL),
substrate (ATP, 100 µM) was then added and incubated for 8–
10 min, the reaction was then stopped with malachite green
reagent. The inorganic phosphate released during the enzymatic
reaction was measured as previously described with the malachite
green assay (Baykov et al., 1988).
TABLE 1 | Antigen used and specificity of the antibodies to mouse and human NTPDase8.
Antigen Conjugation Host Animals per
group
Application
WB IHC ICC FACS
NR Red.
Antibodies to mouse NTPDase8 (accession number: AY364442)
Expression vector encoding mouse NTPDase8 None Rabbit 3 – – – NT NT
Rat 6 – NT – + (2/6) NT
Hamster 6 – NT – – NT
Guinea pig 6 + (5/6) NT – + (5/6) NT
Guinea pig 5 ++ – ++ ++ ++
Peptide 829 (aa 1–14): MGLSWKERVFMALL MAPs Rabbit 2 – – – NT NT
Rat 3 NT – NT NT NT
Hamster 3 NT – NT NT NT
Guinea pig 3 NT – NT NT NT
Peptide 830 (aa 60–74): QWPANKEKDTGVVSQ MAPs Rabbit 2 – – – NT NT
Rat 3 NT – NT NT NT
Hamster 3 NT – NT NT NT
Guinea pig 3 NT – NT NT NT
Peptide 6768 (aa 87–101): SYTSDPTQAGESLKS KLH Rabbit 2 NT + NT NT NT
Peptide 6970 (aa 390–404): VEVSYPGQERWLRDY KLH Rabbit 2 NT – NT NT NT
Peptide 76 (aa 361–441) None Rabbit 3 NT – NT NT NT
Santa Cruz Biotechnologies (sc-160611)1 Unknown Goat N/A NT – NT NT NT
Antibodies to human NTPDase8 (accession number: AY430414)
Expression vector encoding human NTPDase8 None Mouse 92 (4 mAbs) ++ ++ ++ NT +
Aviva Systems Biology (ARP44815_P050)
Peptide aa 110–159
Unknown Rabbit N/A NT – NT NT NT
Unless indicated otherwise with the number of reacting antisera over the total number of animals used for immunization, each animal in the same group reacted similarly
in the experiments presented.
WB, Western blot; NR, non-reduced condition; Red., reduced condition; IHC, immunohistochemistry; ICC, immunocytochemistry; FACS, Fluorescence-activated cell
sorting; NT, not tested; N/A, not applicable; aa, amino acid; mAbs, monoclonal antibodies. Results “−”, absence of reaction or same signal as in the negative control;
“+”, weak positive reaction; “++”, strong and specific reaction and therefore antibody appropriate for research purposes. 1This antibody has been discontinued. 2For
the production of monoclonal antibodies to human NTPDase8, nine BALB/c mice were immunized. Seven out of the nine mice gave a positive reaction on Western blot
in non-reduced conditions. The mouse with the sera with the highest titer was used for the generation of monoclonal antibodies, as described in Section “Materials and
Methods.” The four monoclonal antibodies obtained gave similar results for all experiments as indicated in the table.
Frontiers in Pharmacology | www.frontiersin.org 4 March 2017 | Volume 8 | Article 115
fphar-08-00115 March 8, 2017 Time: 12:17 # 5
Pelletier et al. Characterization of NTPDase8 Antibodies
FIGURE 1 | Specificity of the polyclonal antibodies to mouse
NTPDase8 by Western blot. (A) Lysates (120 µg) for one large well from
COS-7 cells transfected with mouse NTPDase8, were subjected to
electrophoresis and probed with the five guinea pig (mN8-1c;-2c;-3c;-4c; -5c)
antisera [bleeding after the fourth (I4) and fifth (I5) injection] against mouse
NTPDase8 at different dilution (a: 1:1000; b: 1:500; c: 1:2000). (B) NTPDases
specificity tested on lysates from COS-7 cells transfected with mouse
NTPDase1 (mN1), -2 (mN2), -3 (mN3), -8 (mN8) or from non-transfected
COS-7 cells (COS) and probed with the guinea pig anti-mouse NTPDase8
mN8-4c I5 at a dilution of 1:1000. (C) Species specificity tested on lysates
(120 µg; large well) of COS-7 cells transfected with either rat (rN8) or human
(hN8) NTPDase8 and incubated with four guinea pig antisera corresponding
to the bleedings after the fourth (I4), the fifth (I5) and the sixth (I6) injection or
with the preimmune serum at a dilution of 1:500. Control antibodies to rat
NTPDase8, rN8-8c I5 (1:1000) (previously described by Fausther et al., 2007)
and to human NTPDase8, hN8-C5s (0.2 µg/mL) were used to confirm the
presence of rat or human NTPDase8 protein in COS-7 lysates. (D) Lysates
from COS-7 cells transfected with mouse NTPDase8 expression vector (mN8)
or non-transfected (COS) and incubated with either mN8-67L I5 or mN8-68L I6
antiserum diluted 1:500 from rabbits immunized with peptide 6768 conjugated
to KLH. (E) Lysate from COS-7 cells transfected with mouse (mN8) or rat
(rN8) NTPDase8 or non-transfected (COS) and incubated with a commercial
anti-mouse NTPDase8 (1:200) from Santa Cruz Biotechnology Inc. (Dallas,
TX, USA). All gels were run under non-reduced conditions except in panel (D)
and (E) where the protein samples were treated with β-mercaptoethanol.
RESULTS
For many years we struggled to produce antibodies to mouse
NTPDase8. We will present below our unsuccessful attempts that
may help other groups to avoid these problems and improve their
chances of success. We also present an efficient and convenient
technique that we used to obtain excellent antibodies to several
ectonucleotidases that are now available at ectonucleotidases-
ab.com. In addition, we have tested the antibodies produced by
different companies against mouse and human NTPDase8.
Antibodies to Mouse NTPDase8
For the generation of mouse NTPDase8 antibodies, we first
produced short peptides conjugated to KLH or in the form
of MAPs. The number of animals tested for each antigen
and conjugation type is indicated in Table 1. The MAPs was
synthesized with peptide 829 and 830 corresponding to amino
acid 1–14 and 60–74, respectively. These conjugated peptides and
MAPs were injected in rabbits, hamsters, guinea pigs, and rats.
The antiserum obtained for each animal was tested by Western
blot under reduced condition. Note that all antisera generated
from the immunization of peptides as an antigen were tested
only by Western blot under denaturing conditions as this is
the most likely technique that should work with such antigens.
Generally, when no specific signal was obtained by Western
blot with the sera from an animal immunized with peptides, no
further experiments were done. The situation with intact and
native proteins is different and will be described below. From all
the sera with animals immunized with these MAPs, none of them
gave a specific signal for mouse NTPDase8 (Table 1 and data not
shown).
Two other peptides conjugated to KLH, were injected in
rabbits. The antisera from the rabbits injected with the peptide
corresponding to amino acid 87–101 of mouse NTPDase8
showed a signal on lysate of mouse NTPDase8 transfected cells
in Western blot (Figure 1D). Due to high level background, these
antibodies were not further used in other techniques. No specific
signal was obtained with the sera of rabbits injected with the KLH
conjugated peptide corresponding to amino acid 390–404 (data
not shown).
The service of Molecular Biology and Production of Antibody
Service of the Centre de Recherche du CHU de Québec produced
in bacteria a mouse NTPDase8 recombinant section from amino
acid 361 to 441 (peptide 76). The peptide was purified by affinity
chromatography on nickel-nitrilotriacetic acid resin, dialyzed
and injected in rabbits. Again, none of the antisera obtained
detected mouse NTPDase8 by Western blot in reduced condition
(data not shown). Note that the peptides tested above were
selected following in silico analysis using different programs
to determine the hydrophobicity, antigenicity and sequence
homology such as Peptool (BioTools Incorporated, Edmonton,
AB, Canada) and Kyte and Doolittle hydrophobicity scale. The
N-terminal region generally known to represent a good choice for
immunization was also synthetized. Unfortunately, little success
was obtained with these peptides as detailed above.
Injections of mouse NTPDase8 cDNA were then used in
rabbits, hamsters, rats, and guinea pigs. The serum obtained for
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FIGURE 2 | Specificity of the best antisera for immunocytochemistry, immunohistochemistry, and flow cytometry. (A) Immunocytochemistry of COS-7
cells transfected with mouse NTPDase8 (lower panels) or non-transfected COS-7 cells (upper panels) were probed with the guinea pig anti-mouse NTPDase8
mN8-2c I5 (right panels), or with its preimmune serum (left panels), both at a 1:250 dilution. (B) Immunohistochemistry on a liver deficient in NTPDase8 expression
(lower panels) or on a wild type (WT) mouse liver (upper panels) incubated with the preimmune serum (left panels) or the antiserum mN8-3c I5 (right panels) at a
dilution of 1:500. Insets are 2× magnifications. Arrows show stained canaliculi. (C) Flow cytometry on mouse NTPDase8 transfected HEK 293T cells incubated with
the mN8-4c I5 antiserum or its preimmune serum both at 1:80 dilution. In panels (A) and (B), counterstaining of nuclei (blue) was performed with aqueous
hematoxylin. Scale bar 25 µm.
FIGURE 3 | Specificity of the mouse monoclonal antibodies to human NTPDase8 by Western blot. (A) Western blotting using lysates from COS-7 cells
transfected with human NTPDase8 (hN8) or non-transfected cells (COS) in reduced (RED) or in non-reducing conditions (NR) were incubated separately with each
anti-human NTPDase8 hybridoma, hN8-B3s, -D7s, -D7As, and -C5s, as indicated. (B) Specificity of hN8-C5s (0.5 µg/mL) antibody on lysates from COS-7
transfected with human NTPDase1 (hN1), -2 (hN2), -3 (hN3), -8 (hN8), mouse NTPDase8 (mN8), rat NTPDase8 (rN8) or non-transfected cells (COS) in non-reduced
condition. (C) A commercial anti-human NTPDase8 antibody from Aviva Systems Biology tested on lysates from COS-7 transfected with mouse (mN8) or human
(hN8) NTPDase8 as well as non-transfected cells (COS) in reduced condition (left panel). A positive control in non-reduced conditions on a human NTPDase8 COS-7
cell lysate probed with hN8-C5s antibody was performed on the same gel. Additional note. Panels (A) and (B) represent two gels performed in the same time. The
first 12 lanes of panel (A) constitute the first gel and the last four lanes were part of the gel presented in panel (B). The last two lanes of panel (A) (COS and hN8) are
reproduced in the first two lanes of panel (B). Each demarcation shown in panels (A) and (C) represents a lane with non-reduced COS lysates used to stop diffusion
of β-mercaptoethanol. These lanes were cut out of the data presented.
each animal was tested by Western blot. As the antigen here
is the complete native form of mouse NTPDase8 produced by
the host cells, the Western blots were first carried out in non-
reducing conditions. No specific staining was obtained either
with the rabbits, the hamsters or the rats (data not shown).
On the other hand, the antisera developed by guinea pigs gave
a weak signal on lysate from mouse NTPDase8 transfected
COS-7 cells (data not shown). Of all the techniques used and
from all species tested, the guinea pigs injected with cDNA
was the technique and the species from which the best results
were obtained. As the antisera of the first group of guinea
pigs were positive but not sufficiently strong to work with,
we repeated with a second series of five guinea pigs with
the cDNA immunization technique. The sera of those last
5 guinea pigs gave a strong positive signal in Western blot
with different intensity levels at the right molecular weight
(Figure 1A). The detected band in Western blot for mouse
NTPDase8 appears higher than the calculated molecular weight
(54,650 Da) due to eight potential N-linked glycosylation
sites. We do not have an explanation for the difference in
immunoreactivity between the first groups of guinea pigs and the
second group.
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FIGURE 4 | Specificity of hN8-D7S by flow cytometry. Flow cytometry on
human NTPDase8 transfected HEK 293T cells and incubated with an
anti-human NTPDase8 (hN8-D7s) or its isotype control both used at
10 µg/mL.
The cross-reactivity of the two best antibodies (mN8-3cI5 and
mN8-4cI5) was tested on lysates of COS-7 cells transfected with
other closely related members of the mouse E-NTPDase family
as well as with non-transfected cells. Figure 1B shows that the
antiserum mN8-4cI5 does not recognize mouse NTPDase1, -
2, -3 or any other proteins from non-transfected COS-7 cells.
Similar results were obtained for the other antibody tested: mN8-
3cI5 (data not shown). The specificity was also confirmed on
recombinant NTPDase8 from rat and human species, as shown
on Figure 1C, no antiserum after the fourth (I4), the fifth (I5)
and the sixth injection (I6) of those guinea pigs (mN8-2c; -3c; -
4c; -5c) cross-reacted with these two species. Similar results were
obtained with mN8-1c on rat NTPDase8 (data not shown). These
four guinea pig antisera (mN8-2c; -3c; -4c; -5c) were also tested in
reduced conditions against mouse NTPDase8 but none of them
recognized the protein reduced with β-mercaptoethanol (data not
shown).
We next tested whether the best antisera on Western blot
could immunolocalize NTPDase8 by immunocytochemistry and
immunohistochemistry. The antisera mN8-2cI5 gave a strong
positive signal on cells transfected with an expression vector
encoding mouse NTPDase8 (Figure 2A, lower right panel). The
absence of staining in non-transfected COS-7 cells confirmed
the specificity of the reaction (Figure 2A, upper right panel). In
addition, no signal could be detected with the preimmune serum
either on non-transfected or NTPDase8 transfected COS-7 cells
(Figure 2A, left panels). Similar results were obtained with the
mN8-3cI6 and mN8-4cI5 antiserum (data not shown).
These antisera were also efficient and specific to detect the
native NTPDase8 by immunohistochemistry, as evaluated by use
of wild type and knockout mouse for Entpd8 gene. We previously
demonstrated the presence of NTPDase8 in rat (Fausther et al.,
2007) and porcine liver canaliculi (Sévigny et al., 2000). We have
also detected the presence of mRNA in mouse liver (Bigonnesse
et al., 2004) suggesting that this protein may also be found in
the same structure in mouse. As expected, mN8-3cI5 antiserum
stained the canaliculi in the wild type mouse liver but not in
the NTPDase8 knockout mouse (Figure 2B). Similar results were
obtained with mN8-1cI5; -2cI5; -4cI5; -5cI5 antiserum (data not
shown).
Each of the last five guinea pig anti-mouse NTPDase8
antisera was also efficient in flow cytometry. Indeed, they showed
a shift in fluorescence intensity on cells transfected with a
mouse NTPDase8 expression vector when compared with the
preimmune serum (Figure 2C for mN8-4cI5 and data not shown
for the other guinea pig antisera). Overall, these data indicate
that the guinea pig antibodies detect the native mouse NTPDase8
protein.
In contrast to the immunization techniques that use
native proteins as a source of antigen, as in the cDNA
immunization technique with the full gene encoded as we did
here, the commercial anti-mouse NTPDase8 from Santa Cruz
Biotechnology Inc. was generated against a synthetic polypeptide.
Therefore, if it can detect mouse NTPDase8 it must do in
Western blot in denaturing and reduced conditions. In these
conditions, the same non-specific bands were detected in both,
lysates from transfected cells with mouse NTPDase8 and from
non-transfected cells (Figure 1E).
Antibodies to Human NTPDase8
Hybridomas were generated from B-cells of BALB/c mice
injected with human NTPDase8 cDNA. As our previous assays
using only cDNA immunization were ineffective for some
proteins (data not shown), we have made the final boost
with intact HEK 293T cells transfected with the same human
NTPDase8 expression vector to increase the titer and our chances
of success in obtaining hybridomas. Even if the background
would be expected to increase in the sera, this is not an issue
with monoclonal antibodies. With this technique, we obtained
four hybridomas by limiting dilution named hN8-B3s, hN8-C5s,
hN8-D7s, and hN8-D7As, which produced a positive response
in ELISA on lysates of human NTPDase8 transfected cells, and
a negative signal with lysates from non-transfected cells. The
specificity of these monoclonal antibodies was tested by Western
blot, ELISA, and flow cytometry.
The four hybridomas were tested in Western blot on lysates
from COS-7 cells transfected with human NTPDase8 or non-
transfected cells in reduced and non-reduced condition. As
demonstrated in Figure 3A, human NTPDase8 antibodies
recognize human NTPDase8 proteins in both reduced and
non-reduced forms, suggesting that the higher bands observed
over 65 kDa in the non-reduced samples are due to multimer
formation. Indeed, none of these higher molecular weight bands
are detected in the control sample proteins. Human NTPDase8
have a calculated molecular weight of 53,773 Da plus seven
potential glycosylation sites for about 2–4 kDa each. In addition,
the specificity of these four hybridomas was also tested in
Western blot on other human NTPDases (NTPDase1, -2, -3) and
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on other NTPDase8 species (mouse and rat) using lysates from
transfected COS-7 transfected as well as from non-transfected
cells. As illustrated in Figure 3B, the antibody named hN8-
C5s detected only human NTPDase8. No cross-reaction was
observed with human NTPDase1, -2, -3 nor with the mouse
or rat NTPDase8 showing that these antibodies are highly
specific. Similar results were obtained for the three other
antibodies.
The isotype of the antibodies produced by these hybridomas
were determined by ELISA using rat monoclonal antibodies
specific for different mouse immunoglobulin which revealed that
all four hybridomas are IgG2a (data not shown).
The four purified hybridomas anti-human NTPDase8 were
tested by flow cytometry on human NTPDase8 transfected
HEK 293T cells. All hybridomas produced a shift in
the fluorescence at different intensity; the best antibody
for this technique was hN8-D7s (diluted at 10 µg/mL;
Figure 4), data not shown for the three other monoclonal
antibodies.
These four monoclonal antibodies were also tested in enzyme
activity inhibition assays but none of them were able to inhibit
human NTPDase8 (data not shown).
The commercial anti-human NTPDase8 (Aviva Systems
Biology, San Diego, CA, USA) was tested by Western blot.
No specific staining at the expected molecular weight could
be detected in reduced conditions. As seen in Figure 3C,
the bands obtained were the same in the positive samples
[COS-7 cells transfected with human NTPDase8 (hN8)]
and in the negative control [non-transfected COS-7 cells
(COS)].
DISCUSSION
In the present work, we have generated polyclonal antibodies
against mouse NTPDase8 and four hybridomas that produce
IgG2a against human NTPDase8. Many experimental approaches
were necessary to generate antibodies against mouse NTPDase8,
indeed, even if five different peptides were used to produce
antibodies against mouse NTPDase8 injected in different hosts,
and conjugated differently, only the peptides corresponding
to amino acid 87–101 conjugated to KLH injected in rabbits
gave a positive band on Western blot. The immunization with
an expression vector encoding for the full coding sequence
of mouse NTPDase8 in rabbit, guinea pig, rat, and hamster
gave successful result only in guinea pigs (Table 1). This
technique was also useful for the production of antibodies
against several other ectonucleotidases (Sévigny et al., 2002;
Bartel et al., 2006; Vekaria et al., 2006; Fausther et al., 2007,
2012; Martín-Satué et al., 2009). The guinea pig anti-mouse
NTPDase8 antibodies were validated in different techniques.
They are specific and efficient for immunohistochemistry, for
immunocytochemistry, for flow cytometry as well as for Western
blot but only in non-reduced conditions, suggesting that the
epitope is discontinuous and part of a tertiary structure of
the protein involving disulphide bridges. These antibodies were
very specific to mouse NTPDase8 and they did not cross-react
with cells transfected with the other NTPDases that show the
highest homology to NTPDase8, between 39 and 44% identity,
namely NTPDase1, -2, and -3 (Bigonnesse et al., 2004; Lavoie
et al., 2004), or with NTPDase8 from rat and human species.
The other NTPDases which are more different in structures
and in amino acid sequence identity (lower than 25% identity
to mouse NTPDase8) were not tested. All the difficulties that
we encountered to produce antibodies to mouse NTPDase8,
especially those using synthetized peptides, suggests that this
protein is poorly immunogenic.
In addition, the antibody against mouse NTPDase8 allowed
the localization of NTPDase8 in mouse liver canaliculi as we
previously observed for rat NTPDase8 (Fausther et al., 2007).
To generate monoclonal antibodies against human
NTPDase8, an injection of human NTPDase8 transfected
HEK 293T cells at the last boost after several cDNA
immunizations was determined to be an efficient technique.
The monoclonal antibodies against human NTPDase8
were also validated with different techniques. Our results
show that these monoclonal antibodies are efficient in all
techniques tested: Western blot (reduced and non-reduced
conditions), indirect ELISA, immunohistochemistry (data not
shown) and flow cytometry (Table 1). The four hybridomas
may originate from the same original B cell clone since
all experiments performed yielded similar results with
each of the four monoclonal antibodies and that all are
IgG2a.
In addition, we also tested commercial antibodies to mouse
and human NTPDase8. Neither of them detected a specific band
on Western blot under the conditions used in our experiments.
Indeed, the same background bands could be seen in both COS-
7 extracts from cells overexpressing NTPDase8 and in COS-7
extract controls (Figures 1E, 3C). The commercial antibodies
were used at the concentration recommended by the companies.
It is noteworthy that we allowed an overreaction to detect any
minor bands. As a comparative control which is illustrated
in Figure 3C, the amount of cell lysates loaded, containing
human NTPDase8, and time of reaction resulted in an intense
band with the hN8-C5s antibody. Similar results were obtained
when comparing the reaction obtained with mN8-4cI5 antisera
with the antibody from Santa Cruz (Figure 1E and data not
shown).
CONCLUSION
In this work, we generated specific antibodies to mouse and
human NTPDase8 with very convenient cDNA immunization
techniques. These antibodies are useful for Western blot,
ELISA, immunohistochemistry, immunocytochemistry, and flow
cytometry. These antibodies allowed the immunolocalization of
NTPDase8 in mouse liver canaliculi. It is noteworthy that the
commercial antibodies tested here against mouse or human
NTPDase8 failed to give a specific reaction. This reiterates
previously published results evaluating other commercially
available antibodies, which indicate that commercial antibodies
need to be carefully validated before they can be correctly and
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effectively used, e.g., for antibodies against angiotensin II AT2
(Hafko et al., 2013), P2Y6 (Yu and Hill, 2013), and alpha1-
adrenergic receptor subtypes (Jensen et al., 2009).
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